From: Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients
Characteristics | N | EXO-PD-L1 | N | Soluble PD-L1 | ||||
---|---|---|---|---|---|---|---|---|
Low N (%) | High N (%) | p-value | Low N (%) | High N (%) | p-value | |||
Age (years) | 0.528 | 0.083 | ||||||
≤ 60 | 38 | 20 (23.53) | 18 (21.18) | 24 | 15 (31.25) | 9 (18.75) | ||
> 60 | 47 | 22 (25.88) | 25 (29.41) | 24 | 9 (18.75) | 15 (31.25) | ||
Gender | 0.063 | 0.233 | ||||||
Male | 46 | 27 (32.94) | 19 (21.18) | 30 | 17 (35.42) | 13 (27.08) | ||
Female | 39 | 15 (16.47) | 24 (9.41) | 18 | 7 (14.58) | 11 (22.92) | ||
Smoking status | 0.138 | 0.143 | ||||||
Smoker | 26 | 16 (18.82) | 10 (11.77) | 14 | 8 (16.67) | 6 (12.50) | ||
Non-smoker | 59 | 26 (30.59) | 33 (38.82) | 34 | 16 (33.33) | 18 (37.50) | ||
Histology | 0.505 | 0.348 | ||||||
Squamous carcinoma | 12 | 7 (8.24) | 5 (5.88) | 5 | 1 (2.08) | 4 (8.33) | ||
Adenocarcinoma | 73 | 35 (41.18) | 38 (44.70) | 43 | 23 (47.92) | 20 (41.67) | ||
TNM stage | 0.012* | 0.140 | ||||||
I | 47 | 29 (34.12) | 18 (21.18) | 29 | 17(37.50) | 12 (22.92) | ||
II/III/IV | 38 | 13 (15.29) | 25 (29.41) | 19 | 7 (12.50) | 12 (27.08) | ||
Tumor size (cm) | 0.003** | 0.004** | ||||||
≤ 2.5 | 43 | 28 (32.94) | 15 (17.65) | 26 | 18 (37.50) | 8 (16.67) | ||
> 2.5 | 42 | 14 (16.47) | 28 (32.94) | 22 | 6 (12.50) | 16 (33.33) | ||
Lymph node status | 0.031* | 0.131 | ||||||
N0 | 53 | 31 (36.47) | 22 (25.88) | 31 | 18 (37.50) | 13 (27.08) | ||
N1–3 | 32 | 11 (12.94) | 21 (24.71) | 17 | 6 (12.50) | 11 (22.92) | ||
Distant metastasis | 0.026* | 0.220 | ||||||
M0 | 73 | 40 (47.06) | 33 (38.82) | 41 | 22 (45.83) | 19 (39.58) | ||
M1 | 12 | 2 (2.35) | 10 (11.77) | 7 | 2 (4.17) | 5 (10.42) |